We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) recently launched the LUMOS II ILIM, a quantum cascade laser (QCL)-based infrared imaging microscope. The breakthrough innovation sets new performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution.
The latest development is expected to strongly boost Bruker’s CALID segment.
BRKR Stock’s Likely Trend Following the News
Since the announcement on Jan. 8, shares of Bruker have gained 3.3%, finishing yesterday’s session at $62.95. The CALID segment is seeing strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker is driving enhanced productivity through innovations in post-genomic life science molecular and cell biology research, in applied and biopharma applications, as well as in next-gen semiconductor metrology in support of AI. Accordingly, we expect the market sentiment surrounding the BRKR stock to remain positive following this news.
Bruker has a market capitalization of $9.21 billion. Going by the Zacks Consensus Estimate, the company’s 2024 revenues are to increase by 13.1%. In the trailing four quarters, it has delivered an average earnings beat of 5.32%.
Significance of BRKR’s New Microscope
The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both transmission and reflection modes. With a very large field of view and complete automation, it allows for the rapid determination of chemical complexity in biological tissues.
Image Source: Zacks Investment Research
Using AI-powered data evaluation, LUMOS II ILIM workflows allow for discoveries in life science, pharma and disease research. Integration with Bruker’s MALDI Imaging methods enables multimodal imaging to characterize tissues with enhanced analytical depth. The LUMOS II ILIM can also be used for rapid pharmaceutical tablet inspection and particle identification, including automated sampling. The users can harness a Python interface to adapt the LUMOS II ILIM to specific requirements and custom workflows.
Industry Prospects Favoring Bruker Stock
Per a research report, the global infrared imaging market was valued at $7.35 billion in 2023 and is expected to grow at a compound annual rate of 6.1% by 2030. Major companies are focusing on multispectral imaging and the integration of AI and ML (machine learning) to further improve the capabilities in various end-use industries.
Other Developments in Bruker
In December 2024, Bruker announced the launch of the Dimension Nexus atomic force microscope (AFM). With the latest-generation NanoScope 6 controller, this new small-footprint AFM delivers wider access to the company’s exclusive PeakForce Tapping technology and over 50 AFM modes. The upgradability and enhanced ease of use of Dimension Nexus provide an optimal intersection of performance and value for the evolving needs of both growing labs and multi-user facilities.
In addition, Bruker’s 1.2 GHz Ascend Nuclear Magnetic Resonance (NMR) spectrometer has been accepted at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich and the University of Zürich. This is the second 1.2 GHz NMR in Switzerland, which will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis.
BRKR Stock Price Performance
In the past 30 days, Bruker shares have gained 10.1% against the industry’s 1.5% fall.
BRKR’s Zacks Rank and Key Picks
Bruker Corporation currently carries a Zacks Rank #4 (Sell).
Abbott shares have dipped 0.7% in the past year. Estimates for the company’s 2024 earnings per share have remained constant at $4.67 in the past 30 days. ABT’s earnings beat estimates in three of the trailing four quarters and broke even in one, the average surprise being 1.64%. In the last reported quarter, it posted an earnings surprise of 0.83%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have dropped 4.4% in the past year against the industry’s growth of 7.8%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 1.9% to $1.62 in the past 30 days. Shares of the company have surged 77.6% in the past year compared with the industry’s 7.8% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope
Bruker Corporation (BRKR - Free Report) recently launched the LUMOS II ILIM, a quantum cascade laser (QCL)-based infrared imaging microscope. The breakthrough innovation sets new performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution.
The latest development is expected to strongly boost Bruker’s CALID segment.
BRKR Stock’s Likely Trend Following the News
Since the announcement on Jan. 8, shares of Bruker have gained 3.3%, finishing yesterday’s session at $62.95. The CALID segment is seeing strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker is driving enhanced productivity through innovations in post-genomic life science molecular and cell biology research, in applied and biopharma applications, as well as in next-gen semiconductor metrology in support of AI. Accordingly, we expect the market sentiment surrounding the BRKR stock to remain positive following this news.
Bruker has a market capitalization of $9.21 billion. Going by the Zacks Consensus Estimate, the company’s 2024 revenues are to increase by 13.1%. In the trailing four quarters, it has delivered an average earnings beat of 5.32%.
Significance of BRKR’s New Microscope
The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both transmission and reflection modes. With a very large field of view and complete automation, it allows for the rapid determination of chemical complexity in biological tissues.
Image Source: Zacks Investment Research
Using AI-powered data evaluation, LUMOS II ILIM workflows allow for discoveries in life science, pharma and disease research. Integration with Bruker’s MALDI Imaging methods enables multimodal imaging to characterize tissues with enhanced analytical depth. The LUMOS II ILIM can also be used for rapid pharmaceutical tablet inspection and particle identification, including automated sampling. The users can harness a Python interface to adapt the LUMOS II ILIM to specific requirements and custom workflows.
Industry Prospects Favoring Bruker Stock
Per a research report, the global infrared imaging market was valued at $7.35 billion in 2023 and is expected to grow at a compound annual rate of 6.1% by 2030. Major companies are focusing on multispectral imaging and the integration of AI and ML (machine learning) to further improve the capabilities in various end-use industries.
Other Developments in Bruker
In December 2024, Bruker announced the launch of the Dimension Nexus atomic force microscope (AFM). With the latest-generation NanoScope 6 controller, this new small-footprint AFM delivers wider access to the company’s exclusive PeakForce Tapping technology and over 50 AFM modes. The upgradability and enhanced ease of use of Dimension Nexus provide an optimal intersection of performance and value for the evolving needs of both growing labs and multi-user facilities.
In addition, Bruker’s 1.2 GHz Ascend Nuclear Magnetic Resonance (NMR) spectrometer has been accepted at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich and the University of Zürich. This is the second 1.2 GHz NMR in Switzerland, which will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis.
BRKR Stock Price Performance
In the past 30 days, Bruker shares have gained 10.1% against the industry’s 1.5% fall.
BRKR’s Zacks Rank and Key Picks
Bruker Corporation currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Abbott (ABT - Free Report) , Haemonetics (HAE - Free Report) and Phibro Animal Health (PAHC - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott shares have dipped 0.7% in the past year. Estimates for the company’s 2024 earnings per share have remained constant at $4.67 in the past 30 days. ABT’s earnings beat estimates in three of the trailing four quarters and broke even in one, the average surprise being 1.64%. In the last reported quarter, it posted an earnings surprise of 0.83%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have dropped 4.4% in the past year against the industry’s growth of 7.8%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 1.9% to $1.62 in the past 30 days. Shares of the company have surged 77.6% in the past year compared with the industry’s 7.8% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.